RGD peptide (GRGDNP) Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 297

Clinical Trials

Multiple clinical trials are evaluating the diagnostic and therapeutic applications of RGD peptides across early-stage development, spanning Phase I to Phase II. These investigations focus on safety in healthy individuals alongside periodontal conditions such as intrabony defects, periodontitis, and alveolar bone loss. Sponsored by academic institutions including Minia University and corporate entities like RDO Pharm, trial statuses range from completed pharmacokinetic assessments to upcoming interventions involving hydrogel delivery systems for regenerative dental procedures.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06936605	NOT_YET_RECRUITING	Intrabony Defect; Periodontal Diseases; Alveolar Bone Loss	Minia University	2025-04-15
NCT05653245	COMPLETED	Periodontitis	Minia University	2021-03-15	PHASE1; PHASE2
NCT03974685	COMPLETED	Healthy	RDO Pharm.	2018-12-12	PHASE1

(data from https://clinicaltrials.gov, updated on 2025-04-20)

Check the RGD peptide (GRGDNP) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

RGD peptide (GRGDNP) selectively binds to cell-surface integrin receptors, thereby disrupting integrin-mediated cell adhesion to the extracellular matrix and triggering apoptosis via direct activation of caspase-3. By modulating integrin-dependent cellular attachment and matrix remodeling, this mechanism provides the biological rationale for its application in hydrogel delivery formulations targeted at treating periodontal intrabony defects and alveolar bone loss.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).